tirzepatide trial Tirzepatide: First Approval | Drugs SURPASS-CVOT Published: Large Trial Confirms

Survodutide (BI 456906), a novel dual GLP-1 and glucagon receptor agonist, demonstrated weight loss of up to 18.7% over 46 weeks in overweight or obese people

Supports gut health, metabolism & microbiome balance

Lose weight with GLP-1 therapy like semaglutide at Inject Tulsa

Since the results of a Phase 2b clinical trial were published in 2017, the Parkinsons community has focused a lot of attention on a class of diabetes drugs called Glucagon-like peptide-1 (or GLP-1)agonists. Last year, the results of another Phase 2 GLP-1 agonist study in Parkinsons provided further encouraging data

The field of metabolic peptide research has evolved rapidly over the past few years, introducing innovative compounds that continue to expand scientific understanding of metabolic pathways

Buy GLP-3-RT online at SYNEX LABS